Stock Screener App

Gratuito -

Installare

9.74

0.71% -0.07

Pre-mercato: 9.79 0.05 +0.51%

Biocryst Pharmaceuticals Inc (BCRX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BCRX Giù? Forum Previsione

Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie

What is HC Wainwright's Forecast for BCRX Q3 Earnings? - MarketBeat

Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits

How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares - simplywall.st

Discipline and Rules-Based Execution in BCRX Response - Stock Traders Daily

Biocryst Pharmaceuticals Stock Price Forecast. Should You Buy BCRX? - StockInvest.us

RA Capital discloses 6.2% BioCryst (BCRX) holding of 15.8M shares - Stock Titan

Research Analysts Issue Forecasts for BCRX Q4 Earnings - MarketBeat

Wedge Capital Management L L P NC Acquires Shares of 380,801 BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat

BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 5.7%Here's What Happened - MarketBeat

Why Did BioCryst Pharmaceuticals (BCRX) Shares Climb After Its Latest Update? - Yahoo Finance

BioCryst Pharmaceuticals (BCRX) Stock Looks Cheap Even After A 53% Gain - Yahoo Finance

Bank of America Corp DE Buys 3,556,208 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat

Assenagon Asset Management S.A. Buys 120,097 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat

BioCryst (BCRX) Q2 2026 Earnings Call Transcript - The Globe and Mail

Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High? - Yahoo Finance

A Look at BioCryst Pharmaceuticals Inc (BCRX) After 5.1% Gain -- GF Value $12.76 vs Price $10.35 - GuruFocus

BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6%What's Next? - MarketBeat

Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options - Yahoo Finance

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst? - Yahoo Finance

BioCryst Pharmaceuticals, Inc. (BCRX) Investor Outlook: Exploring a 111.57% Potential Upside - DirectorsTalk Interviews

BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation - Stocktwits

Weekly Recap: Q2 revenue jump, raised guidance and Astria R&D charge, shift - TradingView

BioCryst Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded to Strong-Buy at Wall Street Zen - MarketBeat

BCRX SWOT Analysis: Financial Resilience Amidst Challenges Revea - GuruFocus

BioCryst Pharmaceuticals, Inc. (BCRX) Options Chain - Yahoo! Finance Canada

State Street Corporation (BCRX) discloses 15.2M BioCryst shares in 13G filing - Stock Titan

How BioCryst’s Higher 2026 Revenue Guidance and Mixed Earnings Picture Will Impact BioCryst Pharmaceuticals (BCRX) Investors - Sahm

BCRX Maintained by RBC Capital -- Price Target Lowered to $13.00 - GuruFocus

Royal Bank Of Canada Issues Pessimistic Forecast for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price - MarketBeat

H.C. Wainwright Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $32 - Moomoo

BCRX Maintained by Wedbush -- Price Target Lowered to $20.00 - GuruFocus

BioCryst WARN filing reveals 47 jobs affected by Birmingham research center closure - WBMA

Wedbush Issues Pessimistic Forecast for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price - MarketBeat

RBC Adjusts Price Target on BioCryst Pharmaceuticals to $13 From $14, Maintains Outperform Rating - marketscreener.com

BioCryst Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:BCRX) 2026-08-06 - Seeking Alpha

RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $13 - Moomoo

Pacer Advisors Inc. Makes New $14.88 Million Investment in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat

Dimensional Fund Advisors LP Has $25.61 Million Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat

Q2 2026 BioCryst Pharmaceuticals Inc Earnings Call Transcript - GuruFocus

BioCryst Pharmaceuticals Inc (BCRX) (Q2 2026) Earnings Call High - GuruFocus

BioCryst Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $20.82, Implies 131% Upside - TradingView

Astria deal drives large H1 loss at BioCryst Pharmaceuticals (Nasdaq: BCRX) - Stock Titan

BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Earnings Results - MarketBeat

BioCryst Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Wedbush Adjusts BioCryst Pharmaceuticals Price Target to $20 From $21, Maintains Outperform Rating - Yahoo Finance

Earnings call transcript: BioCryst beats Q2 2026 estimates and lifts outlook - Investing.com

BioCryst Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat

BioCryst Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2026 - marketscreener.com

BioCryst Pharmaceuticals Q2 Earnings, Revenue Increase; 2026 Revenue Outlook Raised - marketscreener.com

BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Is BioCryst Pharmaceuticals Inc (BCRX) Undervalued After Q2 Earn - GuruFocus

BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance

North Carolina pharmaceutical company laying off 47 in Hoover, leaving Birmingham area - AL.com

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 FY2026 earnings call transcript - Yahoo Finance

Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q2 EPS $0.30, vs. FactSet Est of $0.15 - marketscreener.com

Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Reports Q2 Revenue $218.2M, vs. FactSet Est of $183.3M - marketscreener.com

BioCryst: Q2 Earnings Snapshot - Yahoo Finance

BioCryst Starts Shipping ORLADEYO Oral Pellets to Pediatric Patients - Stock Titan

BioCryst earnings on deck: Can Orladeyo sustain momentum? - Investing.com

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: Significant Upside Potential with 138% Growth Prospects - DirectorsTalk Interviews

Renaissance Technologies LLC Sells 1,351,831 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat

Perceptive Advisors LLC Acquires 4,271,504 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat

First Trust Advisors LP Buys 425,939 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat

Janus Henderson Group PLC Grows Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat

BioCryst Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:BCRX - TradingView

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Update - MarketBeat

BioCryst Pharmaceuticals (BCRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat

ALKS

$49.06

0.79%

RDY

$12.27

1.21%

ELAN

$23.67

5.15%

NBIX

$152.72

1.26%

VTRS

$16.23

1.18%

UTHR

$499.73

0.31%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters